CD29 (Integrin beta 1) Monoclonal Antibody (TS2/16), Super Bright™ 702, eBioscience™, Invitrogen™

Description

Description: This monoclonal antibody 9A11-CD33 reacts with mouse CD33, also known as Siglec3 and gp67. CD33 belongs to the sialic acid-binding immunoglobulin lectins (Siglec) family that binds to sialic acid-containing glycans on cell surface glycoproteins and glycolipids on mammalian cells. Mouse CD33 binds to short O-linked glycans of certain mucins and sialyl-Tn epitopes. Mouse CD33 is expressed by mature granulocytes, immature myeloid cells, and microglia. Unlike human CD33, mouse CD33 lacks a cytoplasmic ITIM domain and exists as two splice variants that have different cytoplasmic tails. In microglia, CD33 inhibits the phagocytosis of toxic amyloid beta. Applications Reported: This 9A11-CD33 antibody has been reported for use in flow cytometric analysis. Applications Tested: This 9A11-CD33 antibody has been tested by flow cytometric analysis of mouse splenocytes. This may be used at less than or equal to 0.25 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Super Bright 702 is a tandem dye that can be excited with the violet laser line (405 nm) and emits at 702 nm. We recommend using a 710/50 bandpass filter.

ITGB1 (Integrin Subunit Beta 1, beta1 integrin subunit, GPIIa, CD29) is a 110 kDa cell surface glycoprotein that is widely expressed by a variety of cells including all leucocytes. ITGB1 forms non-covalently linked heterodimers with at least 6 different alpha chains (alpha1-alpha6, CDa-f) determining the binding properties of beta1 (VLA) integrins. ITGB1 is a cell adhesion molecule appearing on platelets, as the common Beta subunit of the very late activation antigen (VLA), and as a component of various protein complexes binding to extracellular matrix proteins. Decreased expression of ITGB1 correlates with acquiring multidrug resistance of tumor cells in the presence of anti-tumor drug. ITGB1 is up-regulated in leukocytes during emigration and extravascular migration and appear to be critically involved in regulating the immune cell trafficking from blood to tissue. Further, ITGB1 also regulates tissue damage and disease symptoms related to inflammatory bowel disease. Through an ITGB1-dependent mechanism, fibronectin and type I collagen enhance cytokine secretion of human airway smooth muscle in response to IL-1beta. More than 8 beta subunits with numerous splice variant isoforms have been identified in mammals. There are two major forms of integrin beta1: beta1A and beta1D, which differ in 13 amino acids. The distribution pattern in adult tissues for integrin beta types are mutually exclusive. Beta1A is present in all tissues, except cardiac and skeletal muscle which express the beta1D variant.